Evidence & regulatory context
- Mechanism
- Genetically modified allogeneic human neural stem cell line; no ChEMBL entity expected or found. ClinicalTrials.gov searched for 'F3.ChAT' and for human neural stem cells encoding choline acetyltransferase: zero records. Confirmed zero human trials by search, not assumed.
- Target
- Not recorded
- Injury models
- Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatIschaemia-reperfusionCerebral (MCAO/stroke)Sprague-DawleyIntravenous infusionCell number not recoverable, the exponent is missing from t…At reperfusion, after 2 hours of occlusion
Model: Middle cerebral artery occlusion for 2 hours followed by reperfusion
Intravenous F3.ChAT cells reduced infarct volume and improved cognitive and behavioural outcomes with preserved microvessels and lower oxidative and inflammatory markers, outperforming parental F3 cells.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.